title: [Immunoreactive disorders and their correction in patients with rhegmatogenous retinal detachment complicated by vitreoretinal proliferation].
abstract: Examination of the immunologic state of 73 patients with rhegmatogenous retinal detachment complicated by vitreoretinal proliferation has revealed correlation between the severity of the latter and disturbances in the immune state of the patient's body. 44% of patients with the stage C and 62% of patients with the stage D have immunodeficiency expressed by reduced level of T- and B-lymphocytes and their subpopulation. It is shown that disturbances in immunoreactivity can serve as an unfavourable sign for prognosis of effectiveness of surgical intervention in patients with rhegmatogenous retinal detachment. In 70% of the patients these disturbances lead to unfavourable outcome of the operation. For normalization of the revealed disturbances in the immune state, immunomodulator thymaline was used in a complex treatment of 17 patients. The preparation rose the effectiveness of the treatment in 78% of patients and reduced the number of postoperative complications. It is recommended to study the immunologic state of the patient with rhegmatogenous retinal detachment complicated by vitreoretinal proliferation for the purpose of its further correction and a higher effectiveness of surgical treatment of such patients.
authors.forename: A A
authors.initials: AA
authors.lastname: Vanichkin
authors.forename: A I
authors.initials: AI
authors.lastname: Kovalev
authors.forename: T P
authors.initials: TP
authors.lastname: Mikhaĭlova
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000917:Antibody Formation / Q000187:drug effects / Q000276:immunology; D004341:Drug Evaluation; D005128:Eye Diseases / Q000150:complications / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D007154:Immune System Diseases / Q000188:drug therapy / Q000209:etiology / Q000276:immunology*; D007111:Immunity, Cellular / Q000187:drug effects / Q000276:immunology; D012163:Retinal Detachment / Q000150:complications / Q000188:drug therapy / Q000276:immunology*; D013951:Thymus Hormones / Q000627:therapeutic use; D014822:Vitreous Body
chemical_list: D000276:Adjuvants, Immunologic; D013951:Thymus Hormones; C032805:thymalin
vernacular_title: Narusheniia immunoreaktivnosti i ikh korrektsiia u bol'nykh s regmatogennoĭ otsloĭkoĭ setchatki, oslozhnennoĭ vitreoretinal'noĭ proliferatsieĭ.